ADCYAP1 and migraine disorder: Nevertheless, in a phase 2a, randomized, double-blind, placebo-controlled, three-arm clinical trial aimed to evaluate the efficacy and safety of AMG 301 (a PACAP38 antagonist) in migraine prophylaxis, no statistically significant differences were found between AMG 301 and placebo [131].